Long-term attack rates, as compared with incidence rates, may provide improved cost-estimates in venous thromboembolism. A reply to S. D. Grosse

Charles E. Mahan; Mark T. Holdsworth; Shawn M. Welch; Matt Borrego; Alex C. Spyropoulos

doi:10.1160/TH11-11-0802

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2012; 107(01): 194-195
DOI: 10.1160/TH11-11-0802

Author Correspondence

Schattauer GmbH

Long-term attack rates, as compared with incidence rates, may provide improved cost-estimates in venous thromboembolism. A reply to S. D. Grosse

Authors

Charles E. Mahan

¹New Mexico Heart Institute, Albuquerque, New Mexico, USA
Mark T. Holdsworth

²University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA
Shawn M. Welch

³Cardinal Health Pharmacy Solutions, Lovelace Medical Center, Albuquerque, New Mexico, USA
Matt Borrego

²University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA
Alex C. Spyropoulos

⁴Division of Hematology/Oncology, University of Rochester Medical Center, NY, USA

Abstract

Volltext

Referenzen

References
1 Grosse SD. Incidence-based cost estimates require population-based incidence data: A critique of Mahan et al. Thromb Haemost 2012; 107: 192-193.
2 Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108: 978-981.
3 Heit JA, Silverstein MD, Mohr DN. et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159: 445-453.
4 Pineda LA, Hathwar VS, Grant BJ. Clinical suspicion of fatal pulmonary embolism. Chest 2001; 120: 791-795.
5 Hull RD, Pineo GF, Stein PD. et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001; 135: 858-869.
6 Mismetti P, Laporte S, Darmon JY. et al. Metaanalysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913-930.
7 Douketis JD, Eikelboom JW, Quinlan DJ. et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162: 1465-1471.
8 Vaitkus PT, Leizorovicz A, Cohen AT. et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005; 93: 76-79.
9 Prandoni P, Lensing AW, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
10 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768.
11 Pengo V, Lensing AW, Prins MH. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Eng J Med 2004; 350: 2257-2264.
12 Mohr DN, Silverstein MD, Heit JA. et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc 2000; 75: 1249-1256.
13 Martin B. Research grants: problems and options. Australian Universities' Review 2000; 43: 17-22.
14 Amin A, Spyropoulos AC, Dobesh P. et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis 2010; 29: 326-339.
15 Anderson Jr FA, Wheeler HB, Goldberg RJ. et al. Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med 1994; 154: 669-677.
16 Anderson Jr FA, Wheeler HB, Goldberg RJ. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-938.
17 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
18 Spencer FA, Emery C, Lessard D. et al. The Worcester Venous Thromboembolism Study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
19 Cohen AT, Agnelli G, Anderson Jr FA. et al. VTE impact assessment group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
20 Oger E. for the EPI-GETBO Study Group. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost 2000; 83: 637-801.
21 Park B, Messina L, Dargon P. et al. Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample. Chest 2009; 136: 983-990.
22 Douketis JD, Kearon C, Bates S. et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. J Am Med Assoc 1998; 279: 458-462.
23 Carrier M, Le Gal G, Wells PS. et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578-589.
24 Mahan CE, Holdsworth MT, Welch SM. et al. Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event. Thromb Haemost 2011; 106: 405-415.
25 Mahan CE, Spyropoulos AC. Perioperative anti-thrombotic management and anticoagulant bridging. Canadian J Intern Med 2011; 06 (01) 13-21.
26 The Joint Commission (TJC). Specifications Manual for National Hospital Inpatient Quality Measures. Available at: http://www.jointcommission.org/specifications_manual_for_national_hospital_inpatient_quality_measures/ Accessed November 16, 2011.